Upadacitinib (ABT-494)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Upadacitinib (ABT-494), covering 2017-11-20 to 2017-11-20. Get the full timeline:
Most recent: Clinical Trial Update: A Study in Healthy Adults and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics After Multiple Doses of ABT-494 [Phase 1]